27 February 2022 - JW Therapeutics announced that the National Medical Products Administration of China accepted the supplemental new drug application for its anti-CD19 autologous chimeric antigen receptor T-cell immunotherapy product Carteyva (relmacabtagene autoleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma. 

This is the second marketing application on Carteyva submitted by JW Therapeutics, and is expected to be the first cell therapy product approved in China for the treatment of relapsed or refractory follicular lymphoma patients. 

Carteyva was granted breakthrough therapy designation by NMPA in September 2020.

Read JW Therapeutics press release